Ultromics Ltd. secured $55 million in Series C funding to enhance its AI-based cardiovascular disease detection technology. The capital will be deployed to broaden its U.S. market presence and develop additional AI modules aimed at earlier and more precise diagnosis of heart failure and related conditions. CEO Ross Upton emphasized the role of advanced analytics in transforming cardiac care.